Nanchen, David

Subclinical Thyroid Dysfunction and the Risk of Heart Failure Events: An Individual Participant Data Analysis From 6 Prospective Cohorts

Gencer, B., Collet, T.-H., Virgini, V., Bauer, D. C., Gussekloo, J., Cappola, A. R., Nanchen, D., den Elzen, W. P. J., Balmer, P., Luben, R. N., et al. (2012) · Circulation

Thyroid Disorders and TreatmentsHeart Failure Treatment and Management

Cited by 517

Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors

Li, X. S., Obeid, S., Klingenberg, R., Gencer, B., Mach, F., Räber, L., Windecker, S., Rodondi, N., Nanchen, D., Muller, O., et al. (2017) · European Heart Journal

Gut microbiota and healthAcute Myocardial Infarction Research

Cited by 479

Meta-analysis: Subclinical Thyroid Dysfunction and the Risk for Coronary Heart Disease and Mortality

Ochs, N., Auer, R., Bauer, D. C., Nanchen, D., Gussekloo, J., Cornuz, J., & Rodondi, N. (2008) · Annals of Internal Medicine

Thyroid Disorders and TreatmentsThyroid and Parathyroid Surgery

Cited by 477

Subclinical Thyroid Dysfunction and the Risk of Heart Failure in Older Persons at High Cardiovascular Risk

Nanchen, D., Gussekloo, J., Westendorp, R. G. J., Stott, D. J., Jukema, J. W., Trompet, S., Ford, I., Welsh, P., Sattar, N., Macfarlane, P. W., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Disorders and TreatmentsHeart Failure Treatment and Management

Cited by 211

Eligibility for PCSK9 inhibitors according to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines after acute coronary syndromes

Gencer, B., Koskinas, K. C., Räber, L., Karagiannis, A., Nanchen, D., Auer, R., Carballo, D., Carballo, S., Klingenberg, R., Heg, D., et al. (2017) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 35

Statins for Cardiovascular Prevention According to Different Strategies: A Cost Analysis

Ito, M. K., Nanchen, D., Rodondi, N., Paccaud, F., Waeber, G., Vollenweider, P., & Marques-Vidal, P. (2011) · American Journal Cardiovascular Drugs

Lipoproteins and Cardiovascular HealthHealth Systems, Economic Evaluations, Quality of Life

Cited by 11